TITUSVILLE - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the launch of the next evolution of digital clinical trial design with CHIEF-HF, the first-ever completely decentralized, mobile, indication-seeking clinical study.

To accelerate the study and fast-track results, all contact with participants will be done virtually, with no in-person clinical visits required. Drawing on previous experience, the Company is utilizing smart technology and wearable devices to more quickly and efficiently gather and analyze real-world evidence to assess the effectiveness of canagliflozin in adults with heart failure (HF), with or without type 2 diabetes (T2D). Through a collaboration with global research organization PRA Health Sciences and their innovative mobile clinical trial platform, CHIEF-HF (Canagliflozin: Impact on Health Status, Quality of Life and Functional Status in Heart Failure), will examine the use of canagliflozin compared to placebo on quality of life improvement scales, in participants with either preserved or reduced ejection fraction heart failure.

More about CHIEF-HF

CHIEF-HF will enroll participants 18 years or older who have clinically stable symptomatic HF with a baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) score of >40 and

(C) 2019 Electronic News Publishing, source ENP Newswire